The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...